Literature DB >> 16011519

Induction of interleukin-8 production via nuclear factor-kappaB activation in human intestinal epithelial cells infected with Vibrio vulnificus.

B C Lee1, S H Kim, S H Choi, T S Kim.   

Abstract

Vibrio vulnificus, a Gram-negative estuarine bacterium, is a causative agent of food-borne diseases, such as life-threatening septicaemia and wound infection disease. V. vulnificus penetrating into the epithelial barrier stimulates an inflammatory response in the adjacent mucosa. Therefore, interaction between V. vulnificus and epithelial cells is important for understanding of both the immunology of mucosal surfaces and V. vulnificus. In this study, we investigated the effect and action mechanism of V. vulnificus infection on production of interleukin (IL)-8, a proinflammatory cytokine, in human intestinal epithelial INT-407 cells. V. vulnificus infection significantly induced IL-8 production in a time- and multiplicity of infection (MOI)-dependent manner, as determined by human IL-8 enzyme-linked immunosorbent assay (ELISA). In addition, V. vulnificus infection significantly increased IL-8 mRNA levels in INT-407 cells, indicating that the increased IL-8 production by V. vulnificus occurred at the transcriptional level. V. vulnificus infection also enhanced IL-8 gene promoter activity in INT-407 cells transiently transfected with IL-8 promoter constructs, but this effect was impaired in INT-407 cells transfected with IL-8 promoter constructs deleted or mutated of a kappaB site. V. vulnificus infection increased the nuclear factor-kappaB (NF-kappaB) binding activity to a kappaB site and the degradation of IkappaB-alpha protein in a time- and a MOI-dependent manner. Furthermore, BAY11-7082, an inhibitor of NF-kappaB activation, significantly reduced the IL-8 production, NF-kappaB binding activity and IkappaB-alpha degradation induced by V. vulnificus infection. Taken together, these results indicate clearly that V. vulnificus infection significantly induces IL-8 production in human intestinal epithelial cells via NF-kappaB activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16011519      PMCID: PMC1782178          DOI: 10.1111/j.1365-2567.2005.02185.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

Review 1.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

2.  Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression.

Authors:  A T Gewirtz; T A Navas; S Lyons; P J Godowski; J L Madara
Journal:  J Immunol       Date:  2001-08-15       Impact factor: 5.422

3.  Systematic mutagenesis of the Helicobacter pylori cag pathogenicity island: essential genes for CagA translocation in host cells and induction of interleukin-8.

Authors:  W Fischer; J Püls; R Buhrdorf; B Gebert; S Odenbreit; R Haas
Journal:  Mol Microbiol       Date:  2001-12       Impact factor: 3.501

4.  Involvement of p38 mitogen-activated protein kinase in the induction of interleukin-12 p40 production in mouse macrophages by berberine, a benzodioxoloquinolizine alkaloid.

Authors:  Bok Yun Kang; Su Wol Chung; Daeho Cho; Tae Sung Kim
Journal:  Biochem Pharmacol       Date:  2002-05-15       Impact factor: 5.858

5.  Identification of a group 1-like capsular polysaccharide operon for Vibrio vulnificus.

Authors:  A C Wright; J L Powell; J B Kaper; J G Morris
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

6.  P-fimbriae trigger mucosal responses to Escherichia coli in the human urinary tract.

Authors:  B Wullt; G Bergsten; H Connell; P Röllano; N Gebratsedik; L Hang; C Svanborg
Journal:  Cell Microbiol       Date:  2001-04       Impact factor: 3.715

7.  Lymphotoxin beta receptor induces interleukin 8 gene expression via NF-kappaB and AP-1 activation.

Authors:  Ying-Hsin Chang; Shie-Liang Hsieh; Mei-Chieh Chen; Wan-Wan Lin
Journal:  Exp Cell Res       Date:  2002-08-15       Impact factor: 3.905

8.  Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells.

Authors:  Young D Jung; Fan Fan; David J McConkey; Marina E Jean; Wenbiao Liu; Niels Reinmuth; Oliver Stoeltzing; Syed A Ahmad; Alexander A Parikh; Naofumi Mukaida; Lee M Ellis
Journal:  Cytokine       Date:  2002-05-21       Impact factor: 3.861

9.  Proinflammatory cytokine profile in Vibrio vulnificus septicemic patients' sera.

Authors:  Sung Heui Shin; Dong Hyeon Shin; Phil Youl Ryu; Sun Sik Chung; Joon Haeng Rhee
Journal:  FEMS Immunol Med Microbiol       Date:  2002-06-03

10.  Two nonadjacent regions in enteroaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5.

Authors:  Meghan A Donnelly; Theodore S Steiner
Journal:  J Biol Chem       Date:  2002-08-15       Impact factor: 5.157

View more
  4 in total

Review 1.  Vibrio vulnificus: disease and pathogenesis.

Authors:  Melissa K Jones; James D Oliver
Journal:  Infect Immun       Date:  2009-03-02       Impact factor: 3.441

2.  Macrophage migration inhibitory factor regulates interleukin-6 production by facilitating nuclear factor-kappa B activation during Vibrio vulnificus infection.

Authors:  Chia-Chang Chuang; Yin-Ching Chuang; Wen-Teng Chang; Chi-Chung Chen; Lien-I Hor; A-Ming Huang; Pui-Ching Choi; Chi-Yun Wang; Po-Chin Tseng; Chiou-Feng Lin
Journal:  BMC Immunol       Date:  2010-10-12       Impact factor: 3.615

3.  CCAR2 negatively regulates IL-8 production in cervical cancer cells.

Authors:  Wootae Kim; Jaehyuk Pyo; Byeong-Joo Noh; Joo-Won Jeong; Juhie Lee; Ja-Eun Kim
Journal:  Oncotarget       Date:  2017-12-13

4.  The Keystone commensal bacterium Christensenella minuta DSM 22607 displays anti-inflammatory properties both in vitro and in vivo.

Authors:  Camille Kropp; Katy Le Corf; Karima Relizani; Kevin Tambosco; Ccori Martinez; Florian Chain; Georges Rawadi; Philippe Langella; Sandrine P Claus; Rebeca Martin
Journal:  Sci Rep       Date:  2021-06-01       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.